Pro Share Advisors LLC Arbutus Biopharma Corp Transaction History

Pro Share Advisors LLC

$36.5 Billion
Q2 2024

A detailed history of Pro Share Advisors LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Pro Share Advisors LLC holds 28,618 shares of ABUS stock, worth $109,606. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,618

Previous 34,515 17.09%

Holding current value

$109,606

Previous $89,000 1.12%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$2.52 - $3.63 $14,860 - $21,406	-5,897 Reduced 17.09%	28,618 $88,000
Q1 2024 May 08, 2024	BUY	$2.26 - $2.92 $6,393 - $8,260	2,829 Added 8.93%	34,515 $89,000
Q4 2023 Feb 14, 2024	BUY	$1.69 - $2.54 $7,632 - $11,470	4,516 Added 16.62%	31,686 $79,000
Q3 2023 Nov 13, 2023	BUY	$1.9 - $2.27 $357 - $426	188 Added 0.7%	27,170 $55,000
Q2 2023 Aug 10, 2023	BUY	$2.24 - $3.06 $6,189 - $8,454	2,763 Added 11.41%	26,982 $62,000
Q1 2023 May 11, 2023	SELL	$2.23 - $3.1 $7,445 - $10,350	-3,339 Reduced 12.12%	24,219 $73,000
Q4 2022 Feb 02, 2023	BUY	$1.91 - $2.85 $5,812 - $8,672	3,043 Added 12.41%	27,558 $64,000
Q3 2022 Nov 04, 2022	BUY	$1.88 - $2.88 $1,507 - $2,309	802 Added 3.38%	24,515 $47,000
Q2 2022 Aug 01, 2022	SELL	$1.98 - $3.17 $14,586 - $23,353	-7,367 Reduced 23.7%	23,713 $64,000
Q1 2022 May 10, 2022	SELL	$2.42 - $3.98 $13,355 - $21,965	-5,519 Reduced 15.08%	31,080 $93,000
Q4 2021 Feb 08, 2022	BUY	$3.11 - $4.61 $15,929 - $23,612	5,122 Added 16.27%	36,599 $142,000
Q3 2021 Nov 12, 2021	SELL	$2.65 - $4.62 $16,172 - $28,195	-6,103 Reduced 16.24%	31,477 $135,000
Q2 2021 Aug 13, 2021	BUY	$2.5 - $3.51 $64,575 - $90,663	25,830 Added 219.83%	37,580 $114,000
Q1 2021 May 14, 2021	SELL	$3.14 - $4.84 $4,251 - $6,553	-1,354 Reduced 10.33%	11,750 $39,000
Q4 2020 Feb 09, 2021	BUY	$2.76 - $4.97 $36,167 - $65,126	13,104 New	13,104 $47,000
Q4 2019 Feb 12, 2020	SELL	$0.87 - $2.89 $13,392 - $44,488	-15,394 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$1.34 - $2.4 $6,630 - $11,875	-4,948 Reduced 24.32%	15,394 $23,000
Q2 2019 Aug 13, 2019	SELL	$1.46 - $4.44 $3,416 - $10,389	-2,340 Reduced 10.32%	20,342 $42,000
Q1 2019 May 15, 2019	BUY	$3.41 - $4.57 $549 - $735	161 Added 0.71%	22,682 $81,000
Q4 2018 Feb 14, 2019	SELL	$3.5 - $9.66 $15,365 - $42,407	-4,390 Reduced 16.31%	22,521 $86,000
Q3 2018 Nov 14, 2018	SELL	$7.85 - $12.35 $7,253 - $11,411	-924 Reduced 3.32%	26,911 $254,000
Q2 2018 Aug 13, 2018	BUY	$5.0 - $7.35 $11,910 - $17,507	2,382 Added 9.36%	27,835 $203,000
Q1 2018 May 14, 2018	SELL	$4.4 - $6.05 $18,510 - $25,452	-4,207 Reduced 14.18%	25,453 $127,000
Q4 2017 Feb 14, 2018	BUY	$4.45 - $7.7 $131,987 - $228,382	29,660	29,660 $150,000

Others Institutions Holding ABUS

# of Institutions

137

Shares Held

95.4M

Call Options Held

3.44M

Put Options Held

377K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $574M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Arbutus Biopharma Corp Transaction History